Exabis Library
Welcome to the e-CCO Library!
P577: Drug Induced Liver Injury (DILI) secondary to biologic therapy in IBD: ECCO- CONFER Series
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P577: Mucosal eosinophil abundance in non-inflamed colonic tissue predict response to vedolizumab induction therapy in inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P577: Withdrawal of thiopurines in patients with Ulcerative Colitis in remission
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P578 Inter-observer agreement of an expert panel for gastrointestinal ultrasound in ulcerative colitis
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P578: Adriatic-Balkan regional survey on COVID-19 in Inflammatory Bowel Disease patients
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P578: Evolution of Crohn's disease treatment in clinical practice: a 25 year single centre cohort study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P578: Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P578: Non-medical switch between adalimumab biosimilars and from the originator adalimumab to biosimilars in inflammatory bowel disease patients – a multicentre study on efficacy and drug sustainability
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P578: Therapeutic strategies in the approach of paradoxical psoriasis in IBD: experience of a centre
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P578: Therapy refractory ulcerative colitis patients may benefit from appendectomy: long-term clinical results from a multicentre prospective cohort series
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P579 Randomised open-label controlled trial of ciprofloxacin/doxycycline/hydroxychloroquine combination compared with standard budesonide in active Crohn’s disease (APRICOT)
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P579: Complete disease resolution after allogenic hematopoietic stem cell transplantation in children with very early onset inflammatory disease and no identified monogenic mutation
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P579: Online Education Significantly Improved Gastroenterologists' Knowledge of Treatment Options and Therapeutic Goals in Ulcerative Colitis
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P579: Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P579: Real-world comparison of effectiveness between tofacitinib and ustekinumab in patients with ulcerative colitis exposed to at least one anti-TNF agent: results from the TORUS study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P579: Risk of CMV reactivation in UC patients with previous history of CMV infection following infliximab or vedolizumab treatments
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P579: Wearable Devices Can Predict Disease Activity in inflammatory bowel disease Patients
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P580 Irritable bowel syndrome in inflammatory bowel disease after remission: correlation with remission patterns and inflammation
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P580: Benchmarking IBD Pharmacy Services to optimise, strengthen and align IBD Expert Pharmacy Practice
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P580: Early intestinal ultrasound assessment predicts endoscopic response and remission on anti-TNF treatment in Crohn’s Disease – a prospective longitudinal cohort study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM